The role of MRI in prostate cancer active surveillance

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Johnson, Linda M ^a   Choyke, Peter L ^a   Figg, William D ^a   Turkbey, Baris ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CONSERVATIVE TREATMENT; FOLLOW UP; HUMAN; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REPEAT PROCEDURE; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; BLOOD; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; RADIOGRAPHY;

PROSTATE SPECIFIC ANTIGEN;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84918553798     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/203906     Document Type: Review

References (51)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," CA: Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
2. L. Weißbach and J. Altwein, "Active surveillance or active treatment in localized prostate cancer?" Deutsches Ärzteblatt International, vol. 106, no. 22, pp. 371-376, 2009.
3. K. S. Tseng, P. Landis, J. I. Epstein, B. J. Trock, and H. B. Carter, "Risk stratification of men choosing surveillance for low risk prostate cancer," Journal of Urology, vol. 183, no. 5, pp. 1779-1785, 2010.
4. E. D. Selvadurai,M. Singhera, K. Thomas et al., "Medium-term outcomes of active surveillance for localised prostate cancer," European Urology, vol. 64, no. 6, pp. 981-987, 2013.
5. M. A. Dall'Era, P. C. Albertsen, C. Bangma et al., "Active surveillance for prostate cancer: a systematic review of the literature," European Urology, vol. 62, no. 6, pp. 976-983, 2012.
6. J. E. McNeal, A. A. Villers, E. A. Redwine, F. S. Freiha, and T. A. Stamey, "Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate," Cancer, vol. 66, no. 6, pp. 1225-1233, 1990.
7. R. Choo, L. Klotz, C. Danjoux et al., "Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression," Journal of Urology, vol. 167, no. 4, pp. 1664-1669, 2002.
8. M. R. Cooperberg, J. E. Cowan, J. F. Hilton et al., "Outcomes of active surveillance for men with intermediate-risk prostate cancer," Journal of Clinical Oncology, vol. 29, no. 2, pp. 228-234, 2011.
9. M. Bul, R. C. N. van den Bergh, X. Zhu et al., "Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer," BJU International, vol. 110, no. 11, pp. 1672-1677, 2012.
10. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau, and L. Lemaitre, "Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings," Journal of Urology, vol. 176, no. 6, part 1, pp. 2432-2437, 2006.
11. D. M. Somford, C. M. Hoeks, T. Hambrock et al., "Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer," Investigative Radiology, vol. 48, no. 3, pp. 152-157, 2013.
12. V. Fradet, J. Kurhanewicz, J. E. Cowan et al., "Prostate cancer managed with active surveillance: Role of anatomic MR imaging and MR spectroscopic imaging," Radiology, vol. 256, no. 1, pp. 176-183, 2010.
13. B. H. Park, H. G. Jeon, S. H. Choo et al., "Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance," BJU International, vol. 113, no. 6, pp. 864-870, 2014.
14. D. Margel, S. A. Yap, N. Lawrentschuk et al., "Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study," Journal of Urology, vol. 187, no. 4, pp. 1247-1252, 2012.
15. B. Turkbey, H. Mani, O. Aras et al., "Prostate cancer: can multiparametric mr imaging help identify patients who are candidates for active surveillance?" Radiology, vol. 268, no. 1, pp. 144-152, 2013.
16. A. P. Labanaris, V. Zugor, R. Smiszek, R. Nützel, R. Kühn, and K. Engelhard, "Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology," Magnetic Resonance Imaging, vol. 28, no. 7, pp. 943-946, 2010.
17. A. C. Westphalen, F. V. Coakley, J. Kurhanewicz, G. Reed, Z. J. Wang, and J. P. Simko, "Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features," The American Journal of Roentgenology, vol. 193, no. 3, pp. W238-W243, 2009.
18. J. O. Barentsz, J. Richenberg, R. Clements et al., "ESUR prostate MR guidelines 2012," European Radiology, vol. 22, no. 4, pp. 746-757, 2012.
19. E. M. Lawrence, V. J. Gnanapragasam, A. N. Priest, and E. Sala, "The emerging role of diffusion-weighted MRI in prostate cancer management," Nature Reviews Urology, vol. 9, no. 2, pp. 94-101, 2012.
20. V. A. Morgan, S. F. Riches, S. Giles, D. Dearnaley, and N. M. DeSouza, "Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy," American Journal of Roentgenology, vol. 198, no. 3, pp. 596-602, 2012.
21. V. Panebianco, A. Sciarra, A. Marcantonio et al., "Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer," Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 56, no. 4, pp. 331-342, 2012.
22. C. H. Tan, W. Wei, V. Johnson, and V. Kundra, "Diffusion-weighted MRI in the detection of prostate cancer: metaanalysis," American Journal of Roentgenology, vol. 199, no. 4, pp. 822-829, 2012.
23. B. Nicholson, G. Schaefer, and D. Theodorescu, "Angiogenesis in prostate cancer: biology and therapeutic opportunities," Cancer and Metastasis Reviews, vol. 20, no. 3-4, pp. 297-319, 2001.
24. I. Ocak, M. Bernardo, G. Metzger et al., "Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters," American Journal of Roentgenology, vol. 189, no. 4, p. 849, 2007.
25. P. Kozlowski, S. D. Chang, E. C. Jones, K. W. Berean, H. Chen, and S. L. Goldenberg, "Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis - correlation with biopsy and histopathology," Journal of Magnetic Resonance Imaging, vol. 24, no. 1, pp. 108-113, 2006.
26. T. Kobus, T. Hambrock, C. A. Hulsbergen-Van De Kaa et al., "In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil," European Urology, vol. 60, no. 5, pp. 1074-1080, 2011.
27. T. W. Scheenen, S. W. T. P. J. Heijmink, S. A. Roell et al., "Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility," Radiology, vol. 245, no. 2, pp. 507-516, 2007.
28. K. L. Zakian, K. Sircar, H. Hricak et al., "Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy," Radiology, vol. 234, no. 3, pp. 804-814, 2005.
29. C. Ceylan, O. G. Doluoglu, E. Aglamis, and O. Baytok, "Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume," Journal of the Canadian Urological Association, vol. 8, no. 1-2, pp. E81-E85, 2014.
30. J. S. Wolf Jr., C. J. Bennett, R. R. Dmochowski, B. K. Hollenbeck, M. S. Pearle, and A. J. Schaeffer, "Best practice policy statement on urologic surgery antimicrobial prophylaxis," Journal of Urology, vol. 179, no. 4, pp. 1379-1390, 2008.
31. R. J. Babaian, A. Toi, K. Kamoi et al., "A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy," Journal of Urology, vol. 163, no. 1, pp. 152-157, 2000.
32. J. C. Presti Jr., G. J. O'Dowd, M. C. Miller, R. Mattu, and R. W. Veltri, "Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study," Journal of Urology, vol. 169, no. 1, pp. 125-129, 2003.
33. L. A. Eskew, R. L. Bare, D. L. McCullough, and T. A. Stamey, "Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate," Journal of Urology, vol. 157, no. 1, pp. 199-203, 1997.
34. D. Beyersdorff, A. Winkel, B. Hamm, S. Lenk, S. A. Loening, and M. Taupitz, "MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results," Radiology, vol. 234, no. 2, pp. 576-581, 2005.
35. L. Lemaitre, P. Puech, E. Poncelet et al., "Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings," European Radiology, vol. 19, no. 2, pp. 470-480, 2009.
36. N. B. Delongchamps, M. Rouanne, T. Flam et al., "Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging," BJU International, vol. 107, no. 9, pp. 1411-1418, 2011.
37. P. Puech, E. Potiron, L. Lemaitre et al., "Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens," Urology, vol. 74, no. 5, pp. 1094-1099, 2009.
38. C. M. Moore, N. L. Robertson, N. Arsanious et al., "Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review," European Urology, vol. 63, no. 1, pp. 125-140, 2013.
39. Y. Watanabe, A. Terai, T. Araki et al., "Detectionand localization of prostate cancer with the targeted biopsy strategy based on ADC Map: a prospective large-scale cohort study," Journal of Magnetic Resonance Imaging, vol. 35, no. 6, pp. 1414-1421, 2012.
40. M. M. Siddiqui, S. Rais-Bahrami, H. Truong et al., "Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy," European Urology, vol. 64, no. 5, pp. 713-719, 2013.
41. G. A. Sonn, E. Chang, S. Natarajan et al., "Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen," European Urology, vol. 65, no. 4, pp. 809-815, 2014.
42. N. L. Robertson, C. M. Moore, and M. Emberton, "Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging," The Journal of Urology, vol. 186, no. 4, pp. 1281-1285, 2011.
43. C. M. Moore, "Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group," European Urology, vol. 64, no. 4, pp. 544-552, 2013.
44. G. Ploussard, J. I. Epstein, R. Montironi et al., "The contemporary concept of significant versus insignificant prostate cancer," European Urology, vol. 60, no. 2, pp. 291-303, 2011.
45. D. J. Stevens, "1096 the natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population - 260 patient-years," European Urology Supplements, vol. 11, no. 1, pp. e1096-e1096a, 2012.
46. S. Rais-Bahrami, B. Türkbey, A. R. Rastinehad et al., "Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up," Diagnostic and Interventional Radiology, vol. 20, no. 4, pp. 293-298, 2014.
47. I. M. E. Desar, C. M. L. van Herpen, H. W. M. van Laarhoven, J. O. Barentsz, W. J. G. Oyen, and W. T. A. van der Graaf, "Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy," Cancer Treatment Reviews, vol. 35, no. 4, pp. 309-321, 2009.
48. J. H. Yacoub, S. Verma, J. S. Moulton, S. Eggener, and A. Oto, "Imaging-guided prostate biopsy: conventional and emerging techniques," Radiographics, vol. 32, no. 3, pp. 819-837, 2012.
49. N. K. Yerram, D. Volkin, B. Turkbey et al., "Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer," BJU International, vol. 110, no. 11b, pp. E783-E788, 2012.
50. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw, "Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer," Journal of Clinical Oncology, vol. 28, no. 1, pp. 126-131, 2010.
51. M. R. Cooperberg, P. R. Carroll, and L. Klotz, "Active surveillance for prostate cancer: progress and promise," Journal of Clinical Oncology, vol. 29, no. 27, pp. 3669-3676, 2011.